Albatroz Therapeutics
@albatroztherapeutics.com
Protecting the Extracellular Matrix Albatroz Therapeutics is developing first-in-class antibodies against a novel target critical to the integrity of the extracellular matrix, addressing some of the toughest challenges in human health, beginning with cancer and inflammatory diseases.
Albatroz Therapeutics's Company Logos
Albatroz Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#094873
Catalina Blue
9, 72, 115
204, 85, 24
92, 37, 0, 55
#F8D193
Marzipan
248, 209, 147
37, 88, 77
0, 16, 41, 3
#1C1F20
Shark
28, 31, 32
195, 7, 12
12, 3, 0, 87
About Albatroz Therapeutics
Albatroz Therapeutics is a pre-clinical stage biotechnology company dedicated to revolutionizing the treatment of solid tumors and arthritic disorders. With a strong focus on extracellular matrix (ECM) remodeling, we aim to develop innovative therapies that target these conditions at their core. Our team, led by Frederic Bard, the CEO and Scientific Founder, is driven by a passion for pioneering breakthrough solutions in healthcare.
Supported by Florian Schuster as an Investor & Advisor, Guy Heathers as the CBO and Business Co-Founder, Kristina Rutkute as the Director of Business Development, and Cheng-I Wang as the Head of Antibody Development, we are committed to advancing the field of medicine. Together, we strive to make a positive impact on the lives of patients worldwide. Visit our office at 21 Biopolis Rd, #02-03 Nucleos North Tower, Singapore 138567 and explore our cutting-edge products and services.
That's Albatroz Therapeutics – taking innovation to new heights
Company type
Privately Held
Year founded
2021
Company size
11-50 employees
